Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

• Revenue in USD (TTM)0.00
• Net income in USD-15.08m
• Incorporated2014
• Employees31.00

• Location
  Corvus Pharmaceuticals Inc863 Mitten Rd Ste 102BURLINGAME 94010-1311United StatesUSA
• Phone+1 (302) 658-7581
• Fax+1 (302) 655-5049
• Websitehttps://www.corvuspharma.com/